Belantamab Mafodotin manufacturers
- Belantamab Mafodotin
-
-
2026-06-30
- CAS:2050232-20-5
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 10000KGS
Related articles - Synthesis of Belantamab Mafodotin
- Belantamab Mafodotin is prepared by combining mafodotin with the monoclonal antibody belantamab. A drug linker technology was ....
- Dec 28，2023
|
| | Belantamab Mafodotin Basic information |
| | Belantamab Mafodotin Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Belantamab Mafodotin Usage And Synthesis |
| Uses | Belantamab mafodotin (GSK2857916) is composed of humanized and focused monoclonal antibody against B cell maturation antigen (BCMA) and McMMAF. Belantamab mafodotin has anti-myeloma activity[1][2]. | | in vivo | Belantamab mafodotin signifcantly improves survival compared to vehicle in mice harbouring OPM2 tumours[2]. | Animal Model: | Mice harbouring OPM2 tumours[2] | | Dosage: | 4 mg/kg | | Administration: | IP, twice weekly for 4 doses | | Result: | Signifcantly improves survival compared to vehicle. |
| | References | [1] Hulin C, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020 Feb;21(2):207-221. DOI:10.1016/S1470-2045(19)30788-0
[2] Markham A. Belantamab Mafodotin: First Approval. Drugs. 2020 Oct;80(15):1607-1613. DOI:10.1007/s40265-020-01404-x |
| | Belantamab Mafodotin Preparation Products And Raw materials |
|